Extraintestinal isolates of Escherichia coli : identification and prospects for vaccine development

References

• McBean M, Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986–1997. J. Infect. Dis. 183, 596–603 (2001).
   Google Scholar
• Gransden W, Eykyn SJ, Phillips I, Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev. Infect. Dis. 12, 1008–1018 (1990).
   PubMedGoogle Scholar
• Roberts F, Geere I, Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev. Infect. Dis. 13, 34–46 (1991).
   PubMedGoogle Scholar
• Vastag B. New vaccine decreases rate of nosocomial infections. JAMA 285, 1565 (2001).
   PubMed Web of Science ®Google Scholar
• Siegman-Igra Y, Fourer B, Orni-Wasserlauf R et al. Reappraisal of community-acquired bacteremia: A proposal of a new classification for the spectrum of acquisition of bacteremia. Clin. Infect. Dis. 34, 1431–1439 (2002).
   PubMed Web of Science ®Google Scholar
• Fluit A, Schmitz FJ, Verhoef J; European SENTRY Participant Group. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur. J. Clin. Microbiol. Infect. Dis. 20, 188–191 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard G, Vincent JL, Laterre PF et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).
   PubMed Web of Science ®Google Scholar
• Minino A, Smith B. Deaths: Preliminary data for 2000. National Vital Statistics Reports 49, 1–40 2001.
   Google Scholar
• Russo T, Johnson J. Medical and economic impact of extraintestinal infections due to Escherichia coli: An overlooked epidemic. Microbes and Infect. 5, 449–456 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta K, Scholes D, Stamm W. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 281, 736–738 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton T, Stamm W. Increasing antimicobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. 135, 41–50 (2001).
   PubMed Web of Science ®Google Scholar
• Talan D, Stamm WE, Hooton TM et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 283, 1583–1590 (2000).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among enterobacteriaceae isolates from in-patients and out-patients, 1989–2000: differences in the emergence and epidemiology of resistance across organisms. Clin. Infect. Dis. 38(5), 355–362 (2004).
   Google Scholar
• Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary health region. J. Clin. Microbiol. 43(6), 2844–2849 (2005).
   PubMed Web of Science ®Google Scholar
• Wiener J, Quinn JP, Bradford PA et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281, 517–523 (1999).
   PubMed Web of Science ®Google Scholar
• Angus D, Wax RS. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J. Infect. Dis. 191(9), 1523–1529. Epub 2005 Mar 22 (2005).
   PubMed Web of Science ®Google Scholar
• Ahned R, Lanier J, Pamer E. Immunological memory and infection. In: Immunology of Infectious Diseases. Kaufmann S, Sher A, Ahmed R (Eds). ASM Press, Washington DC, USA, 175–189 (2002).
   Google Scholar
• Russo T, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infection. J. Infect. Dis. 172, 440–445 (1995).
   PubMed Web of Science ®Google Scholar
• Olesen B, Kolmos HJ, Orskov F, Orskov I. Escherichia coli bacteraemia in patients with and without haematological malignancies: a study of strain characters and recurrent episodes. J. Infect. 36(1), 93–100 (1998).
   PubMed Web of Science ®Google Scholar
• Maslow JN, Mulligan ME, Arbeit RD. Recurrent Escherichia coli bacteremia. J. Clin. Microbiol. 32(3), 710–714 (1994).
   PubMed Web of Science ®Google Scholar
• Brauner A, Kaijser B, Kuhn I. Recurrent Escherichia coli bacteraemia – clinical characteristics and bacterial properties. J. Infect. 28(1), 49–57 (1994).
   PubMed Web of Science ®Google Scholar
• Kaijser B, Ahlstedt S. Protective capacity of antibodies against Escherichia coli O and K antigens. Infect. Immun. 17, 286–289 (1977).
   PubMed Web of Science ®Google Scholar
• Salles M, Mandine E, Zalisz R, Guenounou M, Smets P. Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli. J. Infect. Dis. 159, 641–647 (1989).
   PubMed Web of Science ®Google Scholar
• Bolin C, Jensen A. Passive immunization with antibodies against iron-regulated outer membrane proteins protects turkeys from Escherichia coli septicemia. Infect. Immun. 55, 1239–1242 (1987).
   PubMed Web of Science ®Google Scholar
• Kaijser B, Larsson P, Olling S. Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity. Infect. Immun. 20, 78–81 (1978).
   PubMed Web of Science ®Google Scholar
• Kaijser B, Larsson P, Nimmich W, Soderstrom T. Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog. Allergy 33, 275–288 (1983).
   PubMedGoogle Scholar
• Langermann S, Palaszynski S, Barnhart M et al. Prevention of mucosal Escherichia coli infection by Fim-H-adhesin-based systemic vaccination. Science 276, 607–611 (1997).
   PubMed Web of Science ®Google Scholar
• Langermann S, Mollby R, Burlein JE et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181, 774–778 (2000).
   PubMed Web of Science ®Google Scholar
• O’Hanley P, Lalonde G, Ji G. α-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an α-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect. Immun. 59, 1153–1161 (1991).
   PubMed Web of Science ®Google Scholar
• Pecha B, Low D, O’Hanley P. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model: single component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains. J. Clin. Invest. 83, 2102–2108 (1989).
   PubMed Web of Science ®Google Scholar
• Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect. Immun. 71(12), 7164–7169 (2003).
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Uehling DT. Resolution time of Escherichia coli cystitis is correlated with levels of preinfection antibody to the infecting Escherichia coli strain. Urology 45(1), 42–46 (1995).
   PubMed Web of Science ®Google Scholar
• Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 238(24), 2613–2616 (1977).
   PubMed Web of Science ®Google Scholar
• Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 154(6), 1033–1036 (1986).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP). Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. MMWR 40, 1–17 (1991).
   PubMedGoogle Scholar
• Jann B, Jann K. Structure and biosynthesis of the capsular antigens of Escherichia coli. Curr. Top. Microbiol. Immunol. 150, 19–42 (1990).
   PubMed Web of Science ®Google Scholar
• Orskov F Orskov F, Jann B, Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol. Rev. 41, 667–710 (1977).
   PubMedGoogle Scholar
• Whitfield C, Valvano M. Biosynthesis and expression of cell-surface polysaccharides in Gram-negative bacteria. Bacteriol. Rev. 35, 135–246 (1993).
   Google Scholar
• Roberts IS. Bacterial polysaccharides in sickness and in health. The 1995 Fleming Lecture. Microbiology 141(Pt 9), 2023–2031 (1995).
   PubMed Web of Science ®Google Scholar
• Schmidt MA, O'Hanley P, Lark D, Schoolnik GK. Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model. Proc. Natl Acad. Sci. USA 85(4), 1247–1251 (1988).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Hardaway K, Kaack B, Fussell EN, Baskin G. Prevention of pyelonephritis by immunization with P-fimbriae. J. Urol. 131(3): 602–607 (1984).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kaack MB, Baskin G et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG-protein. J. Urol. 171(4), 1682–1685 (2004).
   PubMed Web of Science ®Google Scholar
• Kariyawasam S, Wilkie, BN, Gyles CL. Resistance of broiler chickens to Escherichia coli respiratory tract infection induced bypassively transferred egg-yolk antibodies. Vet. Microbiol. 98(3–4), 273–284 (2004).
   PubMed Web of Science ®Google Scholar
• Vandemaele F, Ververken C, Bleyen N et al. Immunization with the binding domain of FimH, the adhesin of Type 1 fimbriae, does not protect chickens against avian pathogenic Escherichia coli. Avian Pathol. 34(3), 264–272 (2005).
   PubMed Web of Science ®Google Scholar
• Wroblewska-Seniuk K, Selvarangan R, Hart A et al. Dra/AfaE adhesin of uropathogenic Dr/Afa+ Escherichia coli mediates mortality in pregnant rats. Infect. Immun. 73(11), 7597–7601 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon DM, Stern SE, Collignon PJ. Influence of the age and sex of human hosts on the distribution of Escherichia coli ECOR groups and virulence traits. Microbiology 151(Pt. 1), 15–23 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson JR, Kuskowski MA, Gajewski A et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J. Infect. Dis. 191(1), 46–50 (2005).
   PubMed Web of Science ®Google Scholar
• Sannes MR Kuskowski MA, Owens K, Gajewski A, Johnson JR. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J. Infect. Dis. 190(12), 2121–2128 (2004).
   PubMed Web of Science ®Google Scholar
• Snyder JA, Haugen BJ, Buckles EL et al. Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect. Immun. 72(11), 6373–6381 (2004).
   PubMed Web of Science ®Google Scholar
• Russo T, Carlino UB, Mong A, Jodush ST. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect. Immun. 67, 5306–5314 (1999).
   PubMed Web of Science ®Google Scholar
• Russo T, McFadden CD, Carlino-MacDonald UB, Beanan JM, Barnard TJ, Johnson JR. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli. Infect. Immun. 70, 7156–7160 (2002).
   PubMed Web of Science ®Google Scholar
• Dozois C, Daigle F, Curtiss RI. Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogenic Escherichia coli strain. Proc. Natl Acad. Sci. USA 100, 247–252 (2003).
   PubMed Web of Science ®Google Scholar
• Negre VL, Bonacorsi S, Schubert S, Bidet P, Nassif X, Bingen E. The Siderophore receptor IroN, but not the high-pathogenicity Island or the hemin receptor ChuA, contributes to the bacteremic step of Escherichia coli neonatal meningitis. Infect. Immun. 72(2), 1216–1220 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson J, O'Bryan TT, Delavari P et al. Clonal relationships and extended virulence genotypes among Escherichia coli isolates from women with a first or recurrent episode of cystitis. J. Infect. Dis. 183, 1508–1517 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson J, Russo TA, Tarr PI et al. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN(E. coli), among Escherichia coli isolates from patients with urosepsis. Infect. Immun. 68, 3040–3047 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson J, Kuskowski MA, O'Bryan TT, Maslow JN. Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia. J. Infect. Dis. 185, 1439–1447 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson J, Stell AL, Delavari P, Murray AC, Kuskowski M, Gaastra W. Phylogenetic and pathotypic similarities between Escherichia coli isolates from human urinary tract infections in dogs and extraintestinal infections in humans. J. Infect. Dis. 183, 897–906 (2001).
   PubMed Web of Science ®Google Scholar
• Bauer R, Zhang L, Foxman B et al. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection-usp, iha, and iroN (E. coli). J. Infect. Dis. 185, 1521–1524 (2002).
   PubMed Web of Science ®Google Scholar
• Kariyawasam S, Wilkie BN, Hunter DB, Gyles CL. Systemic and mucosal antibody responses to selected cell surface antigens of avian pathogenic Escherichia coli in experimentally infected chickens. Avian Dis. 46(3), 668–678 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson JR, Jelacic S, Schoening LM et al. The IrgA homologue adhesin Iha is an Escherichia coli virulence factor in murine urinary tract infection. Infect. Immun. 73(2), 965–971 (2005).
   PubMed Web of Science ®Google Scholar
• Russo T, Carlino U, Johnson J. Identification of ireA, a new iron regulated virulence gene in an extraintestinal pathogenic isolate of Escherichia coli. Infect. Immun. 69, 6209–6216 (2001).
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307(20), 1225–1230 (1982).
   PubMed Web of Science ®Google Scholar
• Greenman RL, Schein RM, Martin MA et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266(8), 1097–1102 (1991).
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher CJ Jr, Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324(7), 429–436 (1991).
   PubMed Web of Science ®Google Scholar
• Hellman J, Zanzot EM, Loiselle PM et al. Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous Gram-negative bacteria. J. Infect. Dis. 176(5), 1260–1268 (1997).
   PubMed Web of Science ®Google Scholar
• Cross AS, Opal SM, Palardy JE et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21(31), 4576–4587 (2003).
   PubMed Web of Science ®Google Scholar
• O’Hanley P, Marcus R, Baek KH, Denich K, Ji GE. Genetic conservation of HlyA determinants and serological conservation of HlyA: basis for developing a broadly cross-reactive subunit Escherichia coli α-hemolysin vaccine. Infect. Immun. 61(3), 1091–1097 (1993).
   PubMed Web of Science ®Google Scholar
• Linggood MA, Ingram PL. The role of α-haemolysin in the virulence of Escherichia coli for mice. J. Med. Microbiol. 15(1), 23–30 (1982).
   PubMed Web of Science ®Google Scholar
• Rippere-Lampe KE, O'Brien AD, Conran R, Lockman HA. Mutation of the gene encoding cytotoxic necrotizing factor Type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli. Infect. Immun. 69(6), 3954–3964 (2001).
   PubMed Web of Science ®Google Scholar
• Guyer DM, Radulovic S, Jones FE, Mobley HL. Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect. Immun. 70(8), 4539–4546 (2002).
   PubMed Web of Science ®Google Scholar
• Kruze D, Biro K, Holzbecher K, Andrial M, Bossart W. Protection by a polyvalent vaccine against challenge infection and pyelonephritis. Urol. Res. 20, 177–181 (1992).
   Google Scholar
• Uehling DT, Hopkins WJ, James LJ, Balish E. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine. J. Urol. 151(1), 214–216 (1994).
   PubMed Web of Science ®Google Scholar
• Uehling DT, James LJ, Hopkins WJ, Balish E. Immunization against urinary tract infection with a multi-valent vaginal vaccine. J. Urol. 146(1), 223–226 (1991).
   PubMed Web of Science ®Google Scholar
• Grischke EM, Ruttgers H. Treatment of bacterial infections of the female urinary tract by immunization of the patients. Urol. Int. 42(5), 338–341(1987).
   Google Scholar
• Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J. Urol. 170(3), 867–869 (2003).
   PubMed Web of Science ®Google Scholar
• Huber M, Krauter K, Winkelmann G et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int. J. Immunopharmacol. 22(12), 1103–1111 (2000).
   PubMed Web of Science ®Google Scholar
• Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents 19(6), 451–456 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC; Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur. Urol. 47(4), 542–548; discussion 548 (2005).
   PubMed Web of Science ®Google Scholar
• Koukalova D, Krocova Z, Vitek P, Macela A, Hajek V. Immunostimulatory activity of the vaccine used in the treatment of recurrent urinary infections. II. Bratisl. Lek Listy 100(4), 215–257 (1999).
   PubMedGoogle Scholar
• Koukalova D, Reif R, Hajek V et al. Immunomodulation of recurrent urinary tract infections with Urvakol vaccine. Bratisl. Lek Listy 100(5), 246–251 (1999).
   PubMedGoogle Scholar
• Marinova S, Nenkov P, Markova R. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections. Int. J. Immunopathol. Pharmacol. 18(3), 357–473 (2005).
   Google Scholar
• Nenkov P, Mitov I, Marinova S, Markova R. Experimental investigations on the immunomodulating activity of polybacterial preparation for peroral immunotherapy and immunoprophylaxis of uroinfections. Int. J. Immunopharmacol. 17(6), 489–496 (1995).
   PubMed Web of Science ®Google Scholar
• Uehling DT, Hopkins WJ, James LJ, Balish E. Vaginal immunization against induced cystitis in monkeys. J. Urol. 137(2), 327–329 (1987).
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kaack MB, Baskin G, Svenson SB. Vaccination with a formalin-killed P-fimbriated E. coli whole-cell vaccine prevents renal scarring from pyelonephritis in the non-human primate. Vaccine 13(1), 11–16 (1995).
   PubMed Web of Science ®Google Scholar
• Kariyawasam S, Wilkie BN, Gyles CL. Construction, characterization, and evaluation of the vaccine potential of three genetically defined mutants of avian pathogenic Escherichia coli. Avian Dis. 48(2), 287–299 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson J, Delavari P, Stell AL, Whittam TS, Carlino U, Russo TA. Molecular comparison of extraintestinal Escherichia coli isolates of the same electrophoretic lineages from humans and domestic animals. J. Infect. Dis. 183, 154–159 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson JR, Kuskowski MA, Smith K, O'Bryan TT, Tatini S. Antimicrobial-resistant and extraintestinal pathogenic Escherichia coli in retail foods. J. Infect. Dis. 191(7), 1040–1049 (2005).
   PubMed Web of Science ®Google Scholar
• Jeannin P, Magistrelli G, Goetsch L. Outer membrane protein A (OmpA), a new pathogen-associated molecular pattern that interacts with antigen-presenting cells-impact on vaccine strategies. Vaccine 20, A23–A27 (2002).
   Google Scholar
• Jeannin P, Magistrelli G, Herbault N. Outer membrane protein A renders dendritic cells and macrophages responsive to CCL21 and triggers dendritic cell migration to secondary lymphoid organs. Eur. J. Immunol. 33, 326–333 (2003).
   PubMed Web of Science ®Google Scholar
• Russo T, Magistrelli G, Herbault N et al. Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Molec. Microbiol. 9, 357–364 (1993).
   PubMed Web of Science ®Google Scholar
• Russo T, Sharma G, Brown CR, Campagnari AA. The loss of the O4 antigen moiety from the lipopolysaccharide of an extraintestinal isolate of Escherichia coli has only minor effects on serum sensitivity and virulence in vivo. Infect. Immun. 63, 1263–1269 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson JR, Russo TA. Extraintestinal pathogenic Escherichia coli, ‘the other bad E. coli’. J. Lab. Clin. Med. 139(3), 155–162 (2002).
   Google Scholar
• Russo T. Capsule and lipopolysaccharide. In: Escherichia coli, Virulence Mechanisms of a Versatile Pathogen. Donnenberg M (Ed.), Academic Press, London, UK, 379–403. (2002).
   Google Scholar
• Russell M, Mestecky J. Humoral immune response to microbial infections in the genital tract. Microbes Infection 4, 667–677 (2002).
   PubMed Web of Science ®Google Scholar
• Somerville J, Cassiano L, Bainbridge B, Cunningham MD, Darveau RP. A novel Escherichia coli lipid A mutant that produces an anti-inflammatory lipopolysaccharide. J. Clin. Invest. 97, 359–365 (1996).
   PubMed Web of Science ®Google Scholar
• Couch R. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. New Engl. J. Med. 350, 860–861 (2004).
   Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med. 350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar